IL2 and non-small cell lung carcinoma: A phase I clinical study involving eleven patients with metastatic colorectal cancer and one patient with non-small cell lung cancer (NSCLC) has shown that the re-infusion of autologous, TKD/IL-2-activated leukapheresis products is feasible, safe and well-tolerated [15].